What is your assessment of the 9902b low-Gleason-TTP approval route and the significance, if any, of this subject resurfacing now?
It never really went under the surface and has not really been talked about by the company per se. The only reference is, at best, an oblique one - that they have very explicitly said that they will not change 9902b unless it is it clear that they will file on 9902a/9901. I personally don't think that TTP is very likely, but given the proposed mechanism that the company talked about whereby TTP was a difficult endpoint for them, I don't think that they excluded it. (e.g. they didn't say it can't slow a bulky tumor, they just said it takes too long to kick in to be an easy measurement.)
BTW - As you might have guessed, you have 'conversed' with me before. Just would prefer to be anony here.